Prohibits health insurance plans from requiring prior authorization for a new episode of rehabilitative care for twelve visits, or from requiring prior authorization for rehabilitative care for chronic pain for ninety days.
Requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative engaged by the manufacturer and to pay an annual fee for each name listed with the department of business regulation.